Glaxo Starts India Venture to Develop Emerging Market Vaccines
Tuesday, January 29, 2013
GlaxoSmithKline Plc (GSK) agreed to form a joint venture in India to produce a six-in-one vaccine that will immunize children in developing countries against infectious diseases including polio.
The London-based drugmaker has agreed to form a 50-50 venture with India’s Biological E Ltd. to develop a product that would combine Glaxo’s injectable polio shot with a vaccine produced by Biological E that protects against five diseases including diphtheria and tetanus, the companies said in an e- mailed statement on Jan. 28.
- Health Care
- public health